1. Home
  2. EME vs RPRX Comparison

EME vs RPRX Comparison

Compare EME & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EMCOR Group Inc.

EME

EMCOR Group Inc.

N/A

Current Price

$681.08

Market Cap

32.7B

Sector

Industrials

ML Signal

N/A

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

N/A

Current Price

$66.72

Market Cap

28.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EME
RPRX
Founded
1987
1996
Country
United States
United States
Employees
25000
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7B
28.4B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
EME
RPRX
Price
$681.08
$66.72
Analyst Decision
Buy
Buy
Analyst Count
11
8
Target Price
★ $940.50
$65.38
AVG Volume (30 Days)
384.6K
★ 3.0M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
0.24%
★ 1.40%
EPS Growth
★ 30.99
N/A
EPS
★ 24.93
0.71
Revenue
★ $16,986,422,000.00
$2,378,193,000.00
Revenue This Year
$21.88
$47.40
Revenue Next Year
$12.68
$9.10
P/E Ratio
★ $27.26
$94.74
Revenue Growth
★ 16.62
5.06
52 Week Low
$564.92
$36.03
52 Week High
$951.96
$67.71

Technical Indicators

Market Signals
Indicator
EME
RPRX
Relative Strength Index (RSI) 39.03 73.14
Support Level $631.70 $55.48
Resistance Level $768.75 N/A
Average True Range (ATR) 27.07 1.32
MACD -2.44 0.67
Stochastic Oscillator 34.73 90.98

Price Performance

Historical Comparison
EME
RPRX

About EME EMCOR Group Inc.

EMCOR Group Inc is a specialty contractor in the United States and a provider of electrical and mechanical construction and facilities services, building services, and industrial services. Its services are provided to a broad range of commercial, technology, manufacturing, industrial, healthcare, utility, and institutional customers through approximately 100 operating subsidiaries. The company's operating subsidiaries are organized into reportable segments: United States mechanical construction and facilities services, which derives key revenue; United States electrical construction and facilities services; United States building services; United States industrial services; and United Kingdom building services. Geographically, its key revenue is derived from the United States.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: